Presentation to the Trial Steering Committee is expected to occur in October of 2013, after the opening of enrollment into the 5 th cohort. The interim review will focus on safety, tolerability and other clinical parameters of the Company's lead clinical candidate, L-DOS47 for the treatment of non-small cell lung cancer. ( TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the treatment of cancer, today announced that it has completed patient enrolment in the fourth cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 and will perform an interim review of data collected for all subjects enrolled to date. AURORA, ON-(Marketwired - Sep 9, 2013) - Helix BioPharma Corp.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |